Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More

First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published

The American Psychedelic Practitioners Association (APPA) and BrainFutures have published the first-ever set of professional practice guidelines for the provision of psychedelic-assisted therapy. APPA is the national entity advocating for the integration of psychedelics into the U.S. healthcare system. 

The partners say the specificity of the psychedelic therapy model -combining psychedelic administration and therapy in the same session- calls for practitioners to hold “new processes and competencies.” Learn more HERE.

DMT As A Treatment For Stroke? Phase 2 Study Looks Closer

Algernon NeuroScience (AGN Neuro), a subsidiary of Algernon Pharmaceuticals Inc. AGNPF, completed a feasibility study and has finalized its clinical trial design for a 40 patient phase 2 DMT stroke study.

The decision to investigate DMT for stroke treatment was based on the ground-breaking 2020-published rat occlusion stroke study showing that DMT reduced infarct volume and led to an almost full recovery of motor function 30 days after a single treatment with statistical significance. Keep reading HERE.

Dua Lipa Interviews 'Queen Of Psychedelics' Amanda Feilding On Her 6-Decade Exploration Of Psychoactive Drugs

Multi-awarded singer Dua Lipa has been interviewing some interesting folks in her BBC’s “At Your Service” series. This season she invited psychedelics pioneering researcher and advocate Amanda Feilding, known both as the “the Queen of Psychedelics” or also “The High Priestess of LSD.”

Feilding has dedicated six decades of her career to research into consciousness, the exploration of altered states of mind and psychoactive drugs. Today, that work is done through the Beckley Foundation.

The BBC episode moves between past and present use and research on psychedelics. Learn more HERE.

Atai's Q2 2023 & Ibogaine-Opioid Clinical Data, MindMed And COMPASS Pathways, Red Light Holland

Atai Life Sciences ATAI reported its financial results for the second quarter 2023 ended June 30, cash position of $227.5 million. It also released clinical data from its Phase 1 ibogaine treatment for Opioid Use Disorder (OUD,) results reflecting those of prior studies and allowing for the planning of further studies ahead. 

MindMed MNMD also shared its Q2 2023 results, cash position totaling $116.9 million expectedly funding operations until the first half of 2025.

COMPASS Pathways CMPS did so as well, with a $148.2 million cash position together with “important progress” done in laying the commercial groundwork for COMP360 (see the new CPT III code for support services during psychedelics’ administration).

Red Light Holland TRUFF posted financials, but for fiscal years 2021, 2022, and 2023, allowing for a YoY numbers comparison.

The Milestone Round

• atai Life Sciences shared clinical outcomes of r-ketamine for depression, a potential road to subcutaneous at-home use.

• Silo Pharma SILO is advancing a nasal formulation for a ketamine-based treatment toward prevention and relief of anxiety and PTSD.

• Bright Minds DRUG shares surged 91% following positive EEG clinical results of its next-gen psychedelic compound.

• Cybin Inc. CYBN announced and shortly after closed an overnight public offering, for total aggregate gross proceeds of $8,250,000. 

• Awakn Life Sciences AWKNF has become a pure R&D biotech following the sale of its Norway clinics business.

• Reunion Neuroscience REUN completed its take-private setup: Delisting and consideration details.

• The Senate’s appropriations committee approved a spending bill that could amplify marijuana and psychedelics research.

• Incannex’s IXHL Clarion Clinics has started accepting registrations for psychedelic treatment interest.

• PharmAla Biotech PMBHF has filed IP Protection for its novel MDXX molecule, viability as Autism Spectrum treatment.

• Natural psilocybin companies are diversifying: See the latest by Optimi Health OPTHF, Red Light Holland and a European player.

• Holding company Panacea Life Sciences PLSH has entered into a LOI with two psychedelic businesses. 

• Jamaica-Based Kaya Group partnered with Silo Wellness SILFF to launch psychedelic wellness retreats.

• Jamaica’s psilocybin offering flourishes with new organic gummies and retreat by big player Rose Hill.

• Eliza Dushku and her husband Peter Palandjian donated $7.5 million to Brigham And Women's Hospital for substance use disorder research.

• SXSW 2024's voting period for 100+ marijuana and psychedelics panels is on, and check other upcoming events around the globe.

• Zappy Zapolin writes about the new era of mental health and the role of A.I.

See Also: Last Week's Edition Of 'Psyched'

Psychedelics ETF Weekly Performance

AdvisorShares Psychedelics ETF PSIL opened Monday, July 7 at $1.92, slightly below opening July 31 at $1.98. Closing on Friday 11 was at $1.805, considerably lower than prior Friday 4’s at $2.01.

Week’s lowest and highest were also lower than prior weeks: $1.8 vs. $1.88 (Thursday 27) and $1.92 vs. $1.98 (Tuesday 25.)

The ETF’s yearly price range is set between $4.35 and $1.65.

Highest Trading Psychedelics Stocks Friday, August 11

• GH Research GHRS closed at $11.94, descending to $11.65 after hours.

• COMPASS Pathways CMPS closed at $8.11, mounting after hours to $8.26.

• Mind Medicine (MindMed) MNMD closed at $4.26.

• Bright Minds Biosciences DRUG closed at $2.37.

• Enveric Biosciences ENVB closed at $2.72.

• Silo Pharma SILO closed at $2.04.

• atai Life Sciences ATAI closed at $1.68, up after hours to $1.75.

• Incannex Healthcare IXHL closed at $1.6494, slightly up after close to round $1.65.

• Seelos Therapeutics SEEL closed at $1.44, slightly down after close to round $1.4.

• FSD Pharma HUGE closed at $1.36, up after hours to round $1.4.

• Lucy Scientific LSDI closed at $0.86, down after hours to $0.8350.

Take Note: The Benzinga Cannabis Capital Conference Is Back!

The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets TODAY and come join us at the epicenter of cannabis investment and branding!